Intercept Prices 1.5M Share Offering at $62.50/Share

Intercept Pharmaceuticals

announced Tuesday the pricing of an underwritten public offering of 1,500,000 shares of its common stock by certain selling stockholders at a public offering price of $62.50 per share.  In addition, the selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 225,000 shares of common stock. All of the shares in the offering are to be sold by the selling stockholders.  Intercept will not receive any proceeds from the sale of the shares of common stock by the selling stockholders in the offering.  The offering is expected to close on or about October 15, 2013, subject to customary closing conditions.  BofA Merrill Lynch is acting as the sole bookrunning manager and underwriter for the offering.